Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes
In patients with type 2 diabetes who had or were at risk for atherosclerotic cardiovascular disease, treatment with dapagliflozin did not result in a higher or lower rate of MAC...
Publications
1 shownFrequent Co-Authors
Researcher Info
- h-index
- 1
- Publications
- 1
- Citations
- 5,890
- Institution
- AstraZeneca (Sweden)
External Links
Identifiers
- ORCID
- 0000-0003-3309-3840
Impact Metrics
h-index
1
h-index: Number of publications with at least h citations each.